Business Context and Reporting Period
Company: MRI Interventions, Inc. (Note: Request metadata referenced "Clearpoint Neuro, Inc.", but the filing text identifies the registrant as MRI Interventions, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 31, 2016
Principal Event: Entry into a Material Definitive Agreement for a private placement financing transaction (PIPE) and amendments to existing debt instruments.
Key Financial Metrics and Transaction Details
- Financing Transaction: Private placement of 851,000 Units at $5.00 per Unit.
- Aggregate Gross Proceeds: Approximately $4.25 million.
- Unit Composition: One share of common stock plus one warrant to purchase 0.90 shares of common stock.
- Warrant Terms: Exercise price of $5.50 per share; exercisable for five years; includes cashless exercise feature.
- Debt Conversion: $1.75 million of existing 12% Second-Priority Secured Non-Convertible Promissory Notes Due 2019 will automatically convert into the new securities upon closing.
- Placement Agent: Brookline Group, LLC (receiving cash commissions and Placement Agent Warrants).
Material Changes and Agreements
The filing details significant changes to the company's capital structure and obligations effective August 31, 2016:
- Securities Purchase Agreement: Entered into with accredited investors for the sale of Units. Closing is anticipated on or before September 6, 2016, subject to customary conditions.
- Registration Rights Agreement: The Company must file a registration statement with the SEC within 30 calendar days of closing. Failure to file or have the statement declared effective by specific deadlines (75 or 120 days) will trigger liquidated damages payable to investors.
- Debt Amendments (Second Omnibus Amendments):
- Amended two 2019 Notes with an aggregate principal balance of $3 million.
- $1.75 million of this debt converts automatically into the new PIPE securities.
- Exercise price for 13,125 shares underlying existing 2019 Warrants was reduced to $5.50 to match the new Warrant price.
Outlook, Risks, and Contingencies
- Closing Contingency: The transaction is subject to closing conditions. The filing explicitly states there can be no assurance the Financing Transaction will be completed on the described terms or in a timely manner.
- Regulatory Risk: The Company faces potential liquidated damages if the required SEC registration statement is not filed or declared effective within the agreed-upon timeframes.
- Forward-Looking Statements: Actual results may differ materially due to market conditions and the satisfaction of closing conditions. The Company disclaims any obligation to update these statements.
- Unregistered Sales: Securities are being sold in reliance on exemptions under Section 4(a)(2), Rule 506, and Section 3(a)(9) of the Securities Act.
Investor Verification Checklist
- Verify the actual closing date of the Financing Transaction (anticipated on or before September 6, 2016).
- Confirm the filing and effectiveness of the SEC Registration Statement covering the resale of shares and warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for specific indemnification and liquidated damages clauses.
- Monitor the conversion of the $1.75 million in 2019 Notes and the impact on total share count and dilution.
- Check subsequent filings for any updates regarding the satisfaction of closing conditions or changes to the transaction terms.